Market Risers: Aviva plc, GlaxoSmithKline plc , AstraZeneca plc, Admiral Group plc, Direct Line Insurance Group PLC & Legal & General Group Plc

Aviva Plc
[shareaholic app="share_buttons" id_name="post_below_content"]

The trading price for Aviva plc ticker code: LON:AV has stepped up 2.62% or 10.93 points during today’s session so far. Buyers are a positive bunch throughout the session. Range high for the period has seen 428.1 meanwhile the session low reached 416.9. The total volume of shares traded by this point was 2,179,736 with the daily average number around 12,745,046. The 52 week high is 554.6 equating to 137.8 points different to the previous business close and a 52 week low sitting at 410.7 which is a difference of 6.10 points. Aviva plc has a 20 SMA of 449.73 and the 50 day simple moving average now of 473.18. The market cap now stands at £16,326.93m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Aviva plc being recorded at Monday, October 29, 2018 at 11:59:46 AM GMT with the stock price trading at 427.73 GBX.

 

The trading price for GlaxoSmithKline plc company symbol: LON:GSK has risen 1.48% or 22.4 points during today’s session so far. Buyers seem confident while the stock has been in play. The period high was 1535.8 dropping as low as 1512.6. Volume total for shares traded during this period was 3,068,199 with the daily average number around 9,098,020. A 52 week high for the stock is 1631.13 around 121.73 points in difference to the previous days close of business and a 52 week low sitting at 1179.39 a difference of some 330.01 points. GlaxoSmithKline plc has a 20 day moving average of 1523.22 and now its 50 day MA at 1542.84. This puts the market cap at £74,756.36m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Monday, October 29, 2018 at 11:59:59 AM GMT with the stock price trading at 1531.8 GBX.

 

The stock price for AstraZeneca plc with company EPIC: LON:AZN has gained 2.55% or 147 points during the course of today’s session so far. Market buyers have remained positive while the stock has been in play. The periods high has already touched 5914 meanwhile the session low reached 5781. The total volume of shares traded by this point was 475,609 with the daily average number around 2,437,920. The 52 week high for the shares is 6126.4 which comes in at 371.4 points different to the previous business close and a 52 week low sitting at 4544.5 a difference of some 1210.5 points. AstraZeneca plc now has a 20 SMA of 5892.85 with a 50 day MA at 5848.57. The market capitalisation currently stands at £73,022.24m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Monday, October 29, 2018 at 11:59:59 AM GMT with the stock price trading at 5902 GBX.

 

Shares of Admiral Group plc ticker code: LON:ADM has moved up 1.91% or 37 points during today’s session so far. Market buyers seem confident throughout the session. The periods high has already touched 1972.5 and hitting a low of 1934.5. The volume total for shares traded up to this point was 135,607 whilst the daily average number of shares exchanged is just 964,056. The 52 week high price for the shares is 2138 amounting to 203 points difference from the previous days close and the 52 week low at 1794.5 which is a difference of 140.5 points. Admiral Group plc has a 20 day moving average of 2016.18 and a 50 day moving average of 2047.32. The market capitalisation is now £5,645.56m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Admiral Group plc being recorded at Monday, October 29, 2018 at 11:59:41 AM GMT with the stock price trading at 1972 GBX.

 

The trading price for Direct Line Insurance Group PLC with EPIC code: LON:DLG has climbed 2.14% or 6.8 points during today’s session so far. Investors have remained positive throughout the session. The period high was 324.3 meanwhile the session low reached 316.7. The total volume of shares traded by this point was 801,229 whilst the average number of shares exchanged is 5,460,272. The 52 week high for the share price is 397 about 79.7 points different to the previous business close and a 52 week low sitting at 307.8 which is a difference of 9.5 points. Direct Line Insurance Group PLC now has a 20 simple moving average of 327.43 and also a 50 day moving average now of 329.6. The current market cap is £4,395.43m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for Direct Line Insurance Group PLC being recorded at Monday, October 29, 2018 at 11:59:44 AM GMT with the stock price trading at 324.1 GBX.

 

Stock in Legal & General Group Plc with ticker code: LON:LGEN has moved up 2.18% or 5.3 points during today’s session so far. Market buyers are a positive bunch during the session. The period high was 249 while the low for the session was 243.3. Volume total for shares traded at this point reached 4,143,727 with the daily average at 23,406,536. A 52 week high for the stock is 289.45 about 46.05 points different to the previous business close and a 52 week low sitting at 236 is a variance of 7.40 points. Legal & General Group Plc now has a 20 SMA at 251.35 and a 50 day SMA of 255.44. The market capitalisation is now £14,630.33m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Legal & General Group Plc being recorded at Monday, October 29, 2018 at 11:59:51 AM GMT with the stock price trading at 248.7 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Aviva plc announces a strategic acquisition of Direct Line, enhancing its growth and performance. The deal offers benefits for both customers and shareholders.
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
    GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.

      Search

      Search